AFJOG

*Available in South Africa ‡ Indicated for atrophic vaginitis and symptomatic vaginal atrophy due to estrogen deficiency during menopause and post-menopause 1 References: 1. Gynoflor ® approved professional information, August 2023. 2. Mueck AO, Ruan X, Prasauskas V, et al. Treatment of vaginal atrophy with estriol and lactobacilli combination: a clinical review. Climacteric 2018;21(2):140-147. 3. Adcock Ingram Limited. Data on file, March 2024. S2 GYNOFLOR. Each 900 mg vaginal tablet contains 0,03 mg estriol and at least 1 x 10 8 cfu viable Lactobacillus acidophilus. Reg. No.: 55/21.13/0343. For full prescribing information refer to the Professional Information approved by SAHPRA, August 2023. Adcock Ingram Limited. Co. Reg. No.: 1949/034385/06. Private Bag X69, Bryanston, 2021. Customer Care: 0860 ADCOCK/232625. www.adcock.com 2025000001389 February 2025. Start her journey to renewed confidence now! NEW Gynoflor® the first estriol and lactobacilli combination vaginal tablet* to effectively treat symptoms of vaginal atrophy and restore her ecosystem during menopause ‡1,3 • Synergistic action of estriol (0,03 mg) and L acidophilus improves vaginal epithelium within 6-12 days 1,2 • Well tolerated due to the low dose of estriol and local action 1,2 Harmony within. Optimal synergy. 1,2